Emergency Use Authorization and Government-funded Vaccination Information

MVC COVID-19 vaccine is a protein subunit vaccine contains recombinant spike protein of SARS-CoV-2 virus and has been authorized for emergency use by Taiwan Food and Drug Administration, Ministry of Health and Welfare.

For the Emergency Use Authorization information, please refer to the announcement of the Ministry of Health and Welfare.

For the Government-funded Vaccination, please refer to the official website of the Centers for Disease Control.

MVC COVID-19 Vaccine

The MVC COVID-19 Vaccine has been authorized to prevent COVID-19 in individuals over 20 years of age.
Stored at temperature between 2° to 8°C.

Dosing and Schedule

  • 0.5 ml per dose, 2 doses at 28 days apart.
  • Intramuscular injection.


  • The antigen is recombinant spike protein (S-2P) which is licensed from US NIH. The recombinant S-2P protein can maintain the trimeric pre-fusion form to make the antigen more stable.
  • With adjuvant of aluminum hydroxide and CpG 1018 developed by Dynavax.
   Package Insert
Adverse Events Reporting
   Product Safety
  • Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
  • Nov 18, 2020 / Scientific Reports

  • Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
  • Mar 22, 2021 / MedRxiv

  • CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
  • Apr 22, 2021 / Scientific Reports

  • Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
  • Jun 25, 2021 / EClinicalMedicine

  • Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blinded, Randomised, Placebo-Controlled Phase 2 Trial
  • Aug 8, 2021 / MedRxiv